Editas Medicine, Inc.
NMS: EDITLive Quote
📈 ZcoreAI Score
Our AI model analyzes Editas Medicine, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get EDIT Z-Score →About Editas Medicine, Inc.
Healthcare
Biotechnology
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
📊 Fundamental Analysis
Editas Medicine, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -19.2% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -198.1%, which indicates that capital utilization is currently under pressure.
At a current price of $2.94, EDIT currently sits at the 52nd percentile of its 52-week range (Range: $1.18 - $4.54).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$287.74M
Trailing P/E
--
Forward P/E
-3.41
Beta (5Y)
2.04
52W High
$4.54
52W Low
$1.18
Avg Volume
1.74M
Day High
Day Low